Polyclonal anti-idiotypic antibodies (AIA) were generated against human Gal alpha 1,3Gal antibodies (anti-Gal) isolated from a single donor. Specificity of the AIA was demonstrated by selective binding to anti-Gal antibodies (Ab) and absence of reactivity to non-Gal Ab. The idiotopes identified by AIA were present on anti-Gal Ab from all of the human samples evaluated (n=59) as well as on pooled samples, demonstrating that a restricted number of dominant idiotopes characterized the human anti-Gal Ab response. Furthermore, the AIA had cross-species reactivity with baboon serum samples (n=19), suggesting that the overall shape of the anti-Gal Ab combining site is conserved throughout the Old World primates and providing additional evidence of...
Within the idiotype/anti-idiotype network, immunoglobulins act alternatively as reactive molecules a...
Anti-Galalpha1-3Gal antibodies (antialphaGal Ab) are a major barrier to clinical xenotransplantation...
We have been developing A? derivative vaccines with the objective to improve the safety of A? target...
Anti-pig antibodies (APA) were analysed in serum from 28 naïve wild-caught baboons (originating from...
We have previously generated a murine anti-idiotype (Ab2) monoclonal antibody (mAb) to a murine Ab1 ...
Anti-Galalpha 1-3Gal (Gal) antibodies (Ab) play a key role in the rejection of pig cells or organs t...
BackgroundB-cell depletion significantly extends survival of α-1,3-galactosyltranferase knockout (GT...
Polyclonal anti-idiotypic antibodies were raised to three monoclonal antibodies to bovine anti-Mülle...
Anti-Gal is the most abundant natural antibody in humans constituting ~1% of immunoglobulins. Anti-G...
The role of antibodies directed against Galalpha1-3Gal (alpha-Gal) epitopes in porcine-to-primate xe...
Model experiments using anti HLA monoclonal antibodies were performed to apply the immune response o...
The immunogenicity of biopharmaceuticals used in clinical practice remains an unsolved challenge in ...
117 p.Thesis (Ph.D.)--University of Illinois at Urbana-Champaign, 1997.Studies of the regulatory idi...
Natural anti-Gal antibodies (NAb) to Gal epitopes play a key role in the rejection of pig cells or o...
In the pig-to-baboon model, the removal of anti-porcine natural antibodies abrogates hyperacute vasc...
Within the idiotype/anti-idiotype network, immunoglobulins act alternatively as reactive molecules a...
Anti-Galalpha1-3Gal antibodies (antialphaGal Ab) are a major barrier to clinical xenotransplantation...
We have been developing A? derivative vaccines with the objective to improve the safety of A? target...
Anti-pig antibodies (APA) were analysed in serum from 28 naïve wild-caught baboons (originating from...
We have previously generated a murine anti-idiotype (Ab2) monoclonal antibody (mAb) to a murine Ab1 ...
Anti-Galalpha 1-3Gal (Gal) antibodies (Ab) play a key role in the rejection of pig cells or organs t...
BackgroundB-cell depletion significantly extends survival of α-1,3-galactosyltranferase knockout (GT...
Polyclonal anti-idiotypic antibodies were raised to three monoclonal antibodies to bovine anti-Mülle...
Anti-Gal is the most abundant natural antibody in humans constituting ~1% of immunoglobulins. Anti-G...
The role of antibodies directed against Galalpha1-3Gal (alpha-Gal) epitopes in porcine-to-primate xe...
Model experiments using anti HLA monoclonal antibodies were performed to apply the immune response o...
The immunogenicity of biopharmaceuticals used in clinical practice remains an unsolved challenge in ...
117 p.Thesis (Ph.D.)--University of Illinois at Urbana-Champaign, 1997.Studies of the regulatory idi...
Natural anti-Gal antibodies (NAb) to Gal epitopes play a key role in the rejection of pig cells or o...
In the pig-to-baboon model, the removal of anti-porcine natural antibodies abrogates hyperacute vasc...
Within the idiotype/anti-idiotype network, immunoglobulins act alternatively as reactive molecules a...
Anti-Galalpha1-3Gal antibodies (antialphaGal Ab) are a major barrier to clinical xenotransplantation...
We have been developing A? derivative vaccines with the objective to improve the safety of A? target...